Dear All: Following hard on the heels of yesterday’s note about the 14 June 2018 Duke-Margolis workshop on development of non-traditional products, we now have a notice regarding a
Dear All: The idea of using real-world evidence (RWE) as a way to support development of novel agents (including antibiotics!) has always intrigued. As you
Dear All, Apologies for the delay, but I’ve held off on this note until the majority of the presentations from the 3-6 Sep 2019 ASM-ESCMID
Dear All: Below my signature, find details of 4 new meetings and (collectively) 4 active or upcoming grant opportunities. One of the grants has a
REDear All: I just heard to today that FDA is holding a public workshop entitled “Development of Antibacterial Drugs for the Treatment of Nontuberculous Mycobacterial
Dear All: FDA held a workshop (go here for workshop agenda and materials) on 8 Apr 2019 on “Development of Antibacterial Drugs for the Treatment of Nontuberculous
Dear All: Apologies for the back-to-back emails, but this one just came across the transom. In brief, FDA will hold a public meeting on Friday 12
Dear All: There are days when I have the feeling of drinking from a fire hose … and this is one of them! Multiple interesting
Dear All: Sponsored by NIH (NIAID, NINDS, NHLBI, NCATS) and DoD (DTRA), a 2-day workshop on CNS infections and ways to penetrate the blood-brain barrier
Dear All: There is a newly announced FDA workshop on 13 Sep on using real-world evidence. Here is the link and I’ve also reproduced the key background